Royalty Pharma (RPRX) Cash from Financing Activities (2019 - 2026)

Royalty Pharma has disclosed Cash from Financing Activities across 8 years of filings, most recently posting -$273.1 million for Q2 2026.

• In Q2 2026, Cash from Financing Activities rose 46.21% year-over-year to -$273.1 million; the TTM figure through Jun 2026 stood at -$282.7 million (up 86.09% YoY), while the FY2025 annual figure was -$1.2 billion, down 428.39% from the prior year.
• Cash from Financing Activities came in at -$273.1 million for Q2 2026 at Royalty Pharma, roughly flat from -$272.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $1.2 billion in Q2 2024 to a low of -$1.4 billion in Q3 2023.
• Average Cash from Financing Activities over 5 years is -$248.0 million, with a median of -$261.8 million recorded in 2022.
• Year-over-year, Cash from Financing Activities plunged 490.86% in 2023 and soared 433.32% in 2024.
• Over 5 years, Cash from Financing Activities stood at -$265.6 million in 2022, then grew by 12.67% to -$231.9 million in 2023, then fell by 11.24% to -$258.0 million in 2024, then dropped by 16.14% to -$299.6 million in 2025, then rose by 8.83% to -$273.1 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$273.1 million in Q2 2026, -$272.7 million in Q1 2026, and -$299.6 million in Q4 2025.